The Consumer Driven Healthcare Institute?s (CDHCI) quarterly report, ?The Consumer Driven Healthcare (CDHC) Market Data Advisory,? aggregates blind data from millions of actual health savings accounts (HSAs) provided by CDHCI members and partners.
The Consumer Driven Healthcare Institute’s (CDHCI) quarterly report, “The Consumer Driven Healthcare (CDHC) Market Data Advisory,” aggregates blind data from millions of actual health savings accounts (HSAs) provided by CDHCI members and partners. According to the report, total accounts administered in HSA programs on average grew 4% in the first quarter of 2010.
The growth comes amid questions raised by the Patient Protection and Affordable Care Act (PPACA), and how its implementation will affect consumer-driven healthcare.
“Under the PPACA, we anticipate that state health insurance exchanges will allow for inclusion of consumer driven account-based plans that meet the standards prescribed under the law,” says David Randall, executive director of CDHCI in Washington, D.C. “As an example, the Massachusetts Health Connector allows high-deductible health plans to be included as a plan option that employers and individuals can choose from. Further, we expect that consumer driven healthcare will continue to grow as more employers seek these plans as a means of controlling health care costs.”
Additional findings from the report showed employers on average contributed $200 each month into individual HSAs and $238 into family HSAs. Employees, on average, contributed $188 each month into individual HSAs, and $387 into family HSAs.
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Roflumilast Foam Showed Strong Results for Scalp and Body Psoriasis in Teens and Adults
May 7th 2025A new JAMA Dermatology study found that once-daily Zoryve (roflumilast) foam, 0.3%, safely and effectively reduced scalp and body plaque psoriasis symptoms in patients 12 and older, offering a convenient, and more tolerated treatment option that may boost adherence and quality of life.
Read More